Lipids and addiction: How sex steroids, prostaglandins, and cannabinoids interact with drugs of abuse

Annals of the New York Academy of Sciences

Volumn 1282, Issue 1, 2013, Pages 25-38

  Leishman, Emma ^a   Kokesh, Kevin J ^a   Bradshaw, Heather B ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Addiction; Cannabinoid; Lipid signaling

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ALCOHOL; AMPHETAMINE DERIVATIVE; CANNABINOID; COCAINE; FATTY ACID AMIDASE; GLUCOSE; GONADORELIN; INDOMETACIN; ISOPRENALINE; LIPID; METABOTROPIC RECEPTOR 5; PROSTAGLANDIN; SEX HORMONE; TYROSINE 3 MONOOXYGENASE; VASOPRESSIN;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANTICONVULSANT ACTIVITY; ARTICLE; CONVULSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SELF ADMINISTRATION; GABAERGIC TRANSMISSION; GLUCOSE BLOOD LEVEL; HUMAN; LIPIDOMICS; NERVE ENDING; NONHUMAN; NUCLEUS ACCUMBENS; PRESYNAPTIC INHIBITION; SEX DIFFERENTIATION; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTUM;

EID: 84875842193     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12081     Document Type: Article

References (116)

1. Koob, G.F. & N.D. Volkow. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
2. Becker, J.B. 2009. Sexual differentiation of motivation: a novel mechanism? Horm Behav. 55: 646-654.
3. Phoenix, C.H. et al. 1959. Organizing action of prenatally administered testosterone propionate on the tissues mediating mating behavior in the female guinea pig. Endocrinology 65: 369-382.
4. McCarthy, M.M. 2010. How it's made: organisational effects of hormones on the developing brain. J. Neuroendocinol. 22: 736-742.
5. Krebs-Kraft, D.L. et al. 2010. Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior. Proc. Natl. Acad. Sci. U. S. A. 107: 20535-20540.
6. Sato, S.M. et al. 2008. Adolescents and androgens, receptors and rewards. Horm Behav. 53: 647-658.
7. Palmer, R.H. et al. 2009. Developmental epidemiology of drug use and abuse in adolescence and young adulthood: evidence of generalized risk. Drug Alcohol Depend. 102: 78-87.
8. Lynch, W.J., M.E. Roth & M.E. Carroll. 2002. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 164: 121-137.
9. Justice, A.J. & H. de Wit. 2000. Acute effects of estradiol pretreatment on the response to d-amphetamine in women. Neuroendocrinology 71: 51-59.
10. Durdiakova, J., D. Ostatnikova & P. Celec. 2011. Testosterone and its metabolites-modulators of brain functions. Acta. Neurobiol. Exp. (Wars) 71: 434-454.
11. London, S.E. & D.F. Clayton. 2010. Genomic and neural analysis of the estradiol-synthetic pathway in the zebra finch. BMC Neurosci. 11: 46-61.
12. Sim, J.A., M.J. Skynner & A.E. Herbison. 2001. Direct regulation of postnatal GnRH neurons by the progesterone derivative allopregnanolone in the mouse. Endocrinology 142: 4448-4453.
13. Meek, L.R. et al. 1997. Actions of testosterone in prepubertal and postpubertal male hamsters: dissociation of effects on reproductive behavior and brain androgen receptor immunoreactivity. Horm Behav. 31: 75-88.
14. Mermelstein, P.G., J.B. Becker & D.J. Surmeier. 1996. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci. 16: 595-604.
15. Micevych, P.E. & P.G. Mermelstein. 2008. Membrane estrogen receptors acting through metabotropic glutamate receptors: an emerging mechanism of estrogen action in brain. Mol. Neurobiol. 38: 66-77.
16. Pedram, A. et al. 2002. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem. 277: 50768-50775.
17. Dajani, E.Z., T.G. Shahwan & N.E. Dajani. 2003. Prostaglandins and brain-gut axis. J. Physiol. Pharmacol. 54 (Suppl. 4): 155-164.
18. Backon, J. 1989. Vasopressin inhibition via combined head-out water immersion and a prostaglandin E-1 precursor in the treatment of male reproductive failure due to chronic alcohol abuse. Med. Hypotheses 29: 81-83.
19. Funk, C.D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
20. Marnett, L.J. 2009. The COXIB experience: a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 49: 265-290.
21. Narumiya, S., Y. Sugimoto & F. Ushikubi. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79: 1193-1226.
22. Zhang, J. & S. Rivest. 1999. Distribution, regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur. J. Neurosci. 11: 2651-2668.
23. Zhao, H., K. Ohinata & M. Yoshikawa. 2009. Central prostaglandin D(2) exhibits anxiolytic-like activity via the DP(1) receptor in mice. Prostaglandins Other Lipid Mediat. 88: 68-72.
24. Kitaoka, S. et al. 2007. Prostaglandin E2 acts on EP1 receptor and amplifies both dopamine D1 and D2 receptor signaling in the striatum. J. Neurosci. 27: 12900-12907.
25. Serrano, A. & L.H. Parsons. 2011. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol. Ther. 132: 215-241.
26. Di Marzo, V. 1998. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392: 153-175.
27. Devane, W.A. et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
28. Mechoulam, R. et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50: 83-90.
29. Kreitzer, A.C. & W.G. Regehr. 2001. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J. Neurosci. 21: RC174.
30. Kreitzer, A.C. & W.G. Regehr. 2001. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29: 717-727.
31. Varma, N. et al. 2001. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci. 21: RC188.
32. Ohno-Shosaku, T. et al. 2007. Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons. J. Physiol. 584: 407-418.
33. Cravatt, B.F. et al. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
34. Bradshaw, H.B. et al. 2009. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem. 10: 14.
35. McHugh, D. et al. 2010. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11: 44.
36. Blankman, J.L., G.M. Simon & B.F. Cravatt. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14: 1347-1356.
37. Fowler, C.J. 2007. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br. J. Pharmacol. 152: 594-601.
38. Bishay, P. et al. 2010. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PloS One 5: e10628.
39. Pertwee, R.G. 2010. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17: 1360-1381.
40. Howlett, A.C. et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54: 161-202.
41. Pertwee, R.G. et al. 2010. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol. Rev. 62: 588-631.
42. Vasquez, C. & D.L. Lewis. 1999. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19: 9271-9280.
43. Howlett, A.C. et al. 1990. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13: 420-423.
44. Atwood, B.K. & K. Mackie. 2010. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160: 467-479.
45. Adams, I.B. & B.R. Martin. 1996. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91: 1585-1614.
46. Katona, I. et al. 1999. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19: 4544-4558.
47. Rodriguez, J.J., K. Mackie & V.M. Pickel. 2001. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J. Neurosci. 21: 823-833.
48. Mena, M.A. et al. 2002. The role of astroglia on the survival of dopamine neurons. Mol. Neurobiol. 25: 245-263.
49. Di Marzo, V. et al. 2002. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids. 66: 377-391.
50. Ho, K.W., N.J. Ward & D.J. Calkins. 2012. TRPV1: a stress response protein in the central nervous system. Am. J. Neurodegener. Dis. 1: 1-14.
51. Ross, R.A. 2003. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140: 790-801.
52. Fowler, C.J. 2003. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res. Brain Res. Rev. 41: 26-43.
53. Adamczyk, P. et al. 2012. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Res. 1444: 45-54.
54. Di Marzo, V., T. Bisogno & L. De Petrocellis. 2001. Anandamide: some like it hot. Trends Pharmacol. Sci. 22: 346-349.
55. Hwang, S.W. et al. 2000. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. U. S. A. 97: 6155-6160.
56. Kozak, K.R. et al. 2002. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem. 277: 44877-44885.
57. Craib, S.J. et al. 2001. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br. J. Pharmacol. 134: 30-37.
58. Bakker, J. & O. Brock. 2010. Early oestrogens in shaping reproductive networks: evidence for a potential organisational role of oestradiol in female brain development. J. Neuroendocrinol. 22: 728-735.
59. Glanowska, K.M. & S.M. Moenter. 2011. Endocannabinoids and prostaglandins both contribute to GnRH neuron-GABAergic afferent local feedback circuits. J. Neurophysiol. 106: 3073-3081.
60. Farkas, I. et al. 2010. Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology 151: 5818-5829.
61. Clasadonte, J. et al. 2011. Gliotransmission by prostaglandin e(2): a prerequisite for GnRH neuronal function? Front. Endocrinol. 2: 91.
62. Rao, S.P. & S.K. Sikdar. 2006. Astrocytes in 17beta-estradiol treated mixed hippocampal cultures show attenuated calcium response to neuronal activity. Glia 53: 817-826.
63. Camp, D.M. & T.E. Robinson. 1988. Susceptibility to sensitization. II. The influence of gonadal hormones on enduring changes in brain monoamines and behavior produced by the repeated administration of D-amphetamine or restraint stress. Behav. Brain Res. 30: 69-88.
64. Camp, D.M. & T.E. Robinson. 1988. Susceptibility to sensitization. I. Sex differences in the enduring effects of chronic D-amphetamine treatment on locomotion, stereotyped behavior and brain monoamines. Behav. Brain Res. 30: 55-68.
65. Hu, M. & J.B. Becker. 2008. Acquisition of cocaine self-administration in ovariectomized female rats: effect of estradiol dose or chronic estradiol administration. Drug Alcohol Depend. 94: 56-62.
66. Ovtscharoff, W. et al. 1992. Sex differences in densities of dopaminergic fibers and GABAergic neurons in the prenatal rat striatum. J. Comp. Neurol. 323: 299-304.
67. Becker, J.B. & V.D. Ramirez. 1981. Experimental studies on the development of sex differences in the release of dopamine from striatal tissue fragments in vitro. Neuroendocrinology 32: 168-173.
68. Xi, Z.X. et al. 2011. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nature Neurosci. 14: 1160-1166.
69. Pava, M.J. & J.J. Woodward. 2012. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol 46: 185-204.
70. Dildy-Mayfield, J.E. et al. 1996. Actions of long chain alcohols on GABAA and glutamate receptors: relation to in vivo effects. Br. J. Pharmacol. 118: 378-384.
71. Helms, C.M., D.J. Rossi & K.A. Grant. 2012. Neurosteroid influences on sensitivity to ethanol. Front. Endocrinol. 3: 10.
72. Chisari, M. et al. 2010. The sticky issue of neurosteroids and GABA(A) receptors. Trends Neurosci. 33: 299-306.
73. Finn, D.A. et al. 2010. Manipulation of GABAergic steroids: Sex differences in the effects on alcohol drinking- and withdrawal-related behaviors. Horm Behav. 57: 12-22.
74. Pettersson, P. et al. 1990. Fat distribution and steroid hormones in women with alcohol abuse. J. Intern. Med. 228: 311-316.
75. Eriksson, C.J. et al. 2005. Testosterone and alcohol use among adolescent male twins: testing between-family associations in within-family comparisons. Behav. Genet. 35: 359-368.
76. Lenz, B. et al. 2012. Sex hormone activity in alcohol addiction: integrating organizational and activational effects. Prog. Neurobiol. 96: 136-163.
77. Boileau, I. et al. 2003. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49: 226-231.
78. Kucheria, K., R. Saxena & D. Mohan. 1985. Semen analysis in alcohol dependence syndrome. Andrologia 17: 558-563.
79. Mello, N. K., J.H. Mendelson & S.K. Teoh. 1989. Neuroendocrine consequences of alcohol abuse in women. Ann. N. Y. Acad. Sci. 562: 211-240.
80. Hill, M. et al. 2005. Altered profiles of serum neuroactive steroids in premenopausal women treated for alcohol addiction. Steroids 70: 515-524.
81. Gianoulakis, C., X. Dai & T. Brown. 2003. Effect of chronic alcohol consumption on the activity of the hypothalamic-pituitary-adrenal axis and pituitary beta-endorphin as a function of alcohol intake, age, and gender. Alcohol Clin. Exp. Res. 27: 410-423.
82. Frye, C.A. 2011. Novel substrates for, and sources of, progestogens for reproduction. J. Neuroendocrinol. 23: 961-973.
83. Veatch, L.M., T.M. Wright & C.L. Randall. 2007. Only male mice show sensitization of handling-induced convulsions across repeated ethanol withdrawal cycles. Alcohol Clin. Exp. Res. 31: 477-485.
84. Deshmukh, A. et al. 2003. Alcoholic men endorse more DSM-IV withdrawal symptoms than alcoholic women matched in drinking history. J. Stud. Alcohol 64: 375-379.
85. Przybycien-Szymanska, M.M. et al. 2011. Binge-pattern alcohol exposure during puberty induces long-term changes in HPA axis reactivity. PloS One. 6: e18350.
86. Przybycien-Szymanska, M.M., Y.S. Rao & T.R. Pak. 2010. Binge-pattern alcohol exposure during puberty induces sexually dimorphic changes in genes regulating the HPA axis. Am. J. Physiol. Endocrinol. Metab. 298: E320-328.
87. Collier, H.O., W.J. McDonald-Gibson & S.A. Saeed. 1976. Stimulation of prostaglandin biosynthesis by drugs: effects in vitro of some drugs affecting gut function. Br. J. Pharmacol. 58: 193-199.
88. Pennington, S.N. & C.P. Smith, Jr. 1979. The effect of ethanol on thromboxane synthesis by blood platelets. Prostaglandins Med. 2: 43-50.
89. Rotrosen, J. et al. 1980. Ethanol and prostaglandin E1: biochemical and behavioral interactions. Life Sci. 26: 1867-1876.
90. George, F.R. & R.A. Meisch. 1990. Cyclooxygenase inhibitors antagonize the rate-depressant effects of ethanol on fixed-ratio responding. Alcohol 7: 355-360.
91. Grupp, L.A., V. Lau & S. Harding. 1998. The reduction in alcohol intake in rats by isoproterenol is attenuated by indomethacin but not enalapril: relationship to blood glucose levels. Psychopharmacology (Berl) 138: 167-175.
92. Rouzer, C.A. & L.J. Marnett. 2011. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev. 111: 5899-5921.
93. Manno, J.E. et al. 1971. The influence of alcohol and marihuana on motor and mental performance. Clin. Pharmacol. Ther. 12: 202-211.
94. Macavoy, M.G. & D.F. Marks. 1975. Divided attention performance of cannabis users and non-users following cannabis and alcohol. Psychopharmacologia 44: 147-152.
95. Siemens, A.J. & O.L. Doyle. 1979. Cross-tolerance between delta9-tetrahydrocannabinol and ethanol: the role of drug disposition. Pharmacol. Biochem. Behav. 10: 49-55.
96. Pava, M.J. et al. 2012. Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol. Psychopharmacology (Berl) 219: 137-147.
97. Houchi, H. et al. 2005. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30: 339-349.
98. Hungund, B.L. et al. 2003. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J. Neurochem. 84: 698-704.
99. Cheer, J.F. et al. 2007. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J. Neurosci. 27: 791-795.
100. Perra, S. et al. 2005. Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo. Psychopharmacology (Berl) 183: 368-377.
101. Basavarajappa, B.S. et al. 2006. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology 50: 834-844.
102. Cippitelli, A. et al. 2008. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl) 198: 449-460.
103. Gallate, J.E. et al. 1999. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur. J. Pharmacol. 370: 233-240.
104. Gallate, J.E. & I.S. McGregor. 1999. The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716. Psychopharmacology (Berl) 142: 302-308.
105. Economidou, D. et al. 2006. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 183: 394-403.
106. Hansson, A.C. et al. 2007. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32: 117-126.
107. Caille, S. et al. 2007. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J. Neurosci. 27: 3695-3702.
108. Soyka, M. et al. 2008. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J. Clin. Psychopharmacol. 28: 317-324.
109. Vinod, K.Y. et al. 2006. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochem. Int. 49: 619-625.
110. Mitrirattanakul, S. et al. 2007. Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Alcohol Clin. Exp. Res. 31: 855-867.
111. Vinod, K.Y. et al. 2010. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J. Psychiatr. Res. 44: 591-597.
112. Blednov, Y.A. & R.A. Harris. 2009. Deletion of vanilloid receptor (TRPV1) in mice alters behavioral effects of ethanol. Neuropharmacology 56: 814-820.
113. Ortiz, S. et al. 2004. Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol Alcohol 39: 88-92.
114. Pietraszek, A., S. Gregersen & K. Hermansen. 2010. Alcohol and type 2 diabetes. A review. Nutr. Metab. Cardiovasc. Dis 5: 366-375.
115. Ginter, E. & V. Simko. 2008. Ethanol and cardiovascular diseases: epidemiological, biochemical and clinical aspects. Bratisl. Lek. Listy 109: 590-594.
116. Miller, W.L. 1995. Mitochondrial specificity of the early steps in steroidogenesis. J. Steroid Biochem. Mol. Biol. 55: 607-616.